Evidence map›Paper›PMID 27798787›Full record

Trial reportMolecular imaging and biology2017

Initial Experience with Tositumomab and I-131-Labeled Tositumomab for Treatment of Relapsed/Refractory Hodgkin Lymphoma.

Heather Jacene, John Crandall, Yvette L Kasamon, Richard F Ambinder, Steven Piantadosi, Donna Serena, Wayne Kasecamp, Richard L Wahl

Abstract readClinical Trial
PubMed Publisher
In one paragraph

Trial report in Molecular imaging and biology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 1 pooled it
1.5field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 1 synthesis or guideline pooled it, 15 citations in OpenAlex.

  1. Pooled it
  2. Dosimetry in Clinical Radiopharmaceutical Therapy of Cancer: Practicality Versus Perfection in Current Practice.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2021
    Review
  3. Normal-Tissue Tolerance to Radiopharmaceutical Therapies, the Knowns and the Unknowns.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2021
    Article
  4. Review
  5. Review
  6. Combination Radioimmunotherapy Strategies for Solid Tumors.International journal of molecular sciences · 2019
    Review
  7. Early evaluation of tumor response toEuropean radiology · 2019
    Article
  8. Article
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Heather JaceneDivision of Nuclear Medicine, Department of Radiology, Johns Hopkins University, Baltimore, MD, USA. hjacene@partners.org.ORCID 0000-0001-7167-078X
John CrandallDivision of Nuclear Medicine, Department of Radiology, Johns Hopkins University, Baltimore, MD, USA.
Yvette L KasamonDepartment of Oncology, Johns Hopkins University, Baltimore, MD, USA.
Richard F AmbinderDepartment of Oncology, Johns Hopkins University, Baltimore, MD, USA.
Steven PiantadosiSamuel Oschin Comprehensive Cancer Institute, Cedars-Sinai, Los Angeles, CA, USA.
Donna SerenaDivision of Nuclear Medicine, Department of Radiology, Johns Hopkins University, Baltimore, MD, USA.
Wayne KasecampDivision of Nuclear Medicine, Department of Radiology, Johns Hopkins University, Baltimore, MD, USA.
Richard L WahlDivision of Nuclear Medicine, Department of Radiology, Johns Hopkins University, Baltimore, MD, USA.
Johns Hopkins University · USCedars-Sinai Medical Center · US

Funding

Treatment of lymphoma by death receptor induced apoptosisP50CA096888 · NCI · JOHNS HOPKINS UNIVERSITY · PI AMBINDER, RICHARD FREDERICK · 2002 to 2009
$13.6M
NCI NIH HHS P50 CA096888
6 · The paper itself

Abstract

purposeTo determine the maximum tolerated dose (MTD) of [ PROCEDURES: Separate dose-finding studies were performed for patients with and without prior transplant. A single therapeutic total body radiation dose (TBD) of [

resultsTwelve patients (nine classical HL, three lymphocyte-predominant [LP] HL) completed two dosing levels (n = 3 each) in the post-transplant (55 cGy, 79 cGy) and no transplant (75 cGy, 87 cGy) groups. Hematologic toxicities were common and transient. Twelve weeks after [

conclusionsTositumomab and [

Indexed as

AdultAntibodies, MonoclonalCohort StudiesDose-Response Relationship, RadiationFemaleHodgkin DiseaseHumansMaleMiddle AgedNeoplasm Recurrence, LocalTreatment OutcomeWhole-Body IrradiationYoung AdultAntibodies, Monoclonaltositumomab I-131[131I]tositumomabBexxarFDGHodgkinHodgkin lymphoma

Identifiers

PMID27798787
OpenAlexW2541172026

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.